INFOGRAPHIC: Going into 2022, there were high expectations for deal-making, but industry continues to face significant headwinds. In Vivo's sister publication Scrip reviewed M&A and alliance activity for the first half of the year to track how business development is shaping up in 2022.
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
